Literature DB >> 24914333

Hepatitis B virus infection and intrahepatic cholangiocarcinoma.

Hua-Bang Zhou1, Jing-Yi Hu1, He-Ping Hu1.   

Abstract

Intrahepatic cholangiocarcinoma (ICC) is a devastating malignant tumor arising from the peripheral intrahepatic bile duct epithelium. The incidence and mortality of ICC is markedly increasing over the past two decades worldwide, though the cause for this rise in incidence is unclear, thus intensifying the search for alternative etiological agents and pathogenetic mechanisms. Hepatolithiasis, primary sclerosing cholangitis, parasitic infection (Opisthorchis viverrini or Clonorchis sinensis), fibropolycystic liver disease, and chemical carcinogen exposure are thought to be the risk factors for ICC. Nevertheless, the majority of ICC patients do not have any of these risk factors, and none of the established risk factors can explain the recent increasing trend of ICC. Therefore, identifying other risk factors may lead to the prevention and early detection of ICC. Chronic hepatitis B virus (HBV) infection is the predominant cause of hepatocellular carcinoma in HBV-endemic areas. This review discusses the evidence implicating chronic HBV infection as a likely etiology of ICC and the pathogenetic mechanisms that might be involved.

Entities:  

Keywords:  Epidemiology; Etiopathogenesis; Hepatitis B virus; Intrahepatic cholangiocarcinoma

Mesh:

Substances:

Year:  2014        PMID: 24914333      PMCID: PMC4024782          DOI: 10.3748/wjg.v20.i19.5721

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  84 in total

1.  Differentiation of multicentric origin from intra-organ metastatic spread of hepatocellular carcinomas by comparative genomic hybridization.

Authors:  L Wilkens; M Bredt; P Flemming; J Klempnauer; H Heinrich Kreipe
Journal:  J Pathol       Date:  2000-09       Impact factor: 7.996

2.  Hepatitis B virus infection: a favorable prognostic factor for intrahepatic cholangiocarcinoma after resection.

Authors:  Hua-Bang Zhou; Hui Wang; Yu-Qiong Li; Shuang-Xi Li; Hao Wang; Dong-Xun Zhou; Qian-Qian Tu; Qing Wang; Shan-Shan Zou; Meng-Chao Wu; He-Ping Hu
Journal:  World J Gastroenterol       Date:  2011-03-14       Impact factor: 5.742

3.  Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database.

Authors:  Tania M Welzel; Barry I Graubard; Stefan Zeuzem; Hashem B El-Serag; Jessica A Davila; Katherine A McGlynn
Journal:  Hepatology       Date:  2011-06-30       Impact factor: 17.425

Review 4.  Primary liver cancer: worldwide incidence and trends.

Authors:  F Xavier Bosch; Josepa Ribes; Mireia Díaz; Ramon Cléries
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

Review 5.  Intrahepatic cholangiocarcinoma: macroscopic type and stage classification.

Authors:  Susumu Yamasaki
Journal:  J Hepatobiliary Pancreat Surg       Date:  2003

6.  Risk factors for intrahepatic cholangiocarcinoma: a case-control study in China.

Authors:  Yan-Ming Zhou; Zheng-Feng Yin; Jia-Mei Yang; Bin Li; Wen-Yu Shao; Feng Xu; Yu-Lan Wang; Dian-Qi Li
Journal:  World J Gastroenterol       Date:  2008-01-28       Impact factor: 5.742

7.  Hepatitis C virus infection as a likely etiology of intrahepatic cholangiocarcinoma.

Authors:  Satoshi Yamamoto; Shoji Kubo; Seikan Hai; Takahiro Uenishi; Takatsugu Yamamoto; Taichi Shuto; Shigekazu Takemura; Hiromu Tanaka; Osamu Yamazaki; Kazuhiro Hirohashi; Takashi Tanaka
Journal:  Cancer Sci       Date:  2004-07       Impact factor: 6.716

Review 8.  Increasing incidence of intrahepatic cholangiocarcinoma and its relationship to chronic viral hepatitis.

Authors:  Kwang-Yu Chang; Jang-Yang Chang; Yun Yen
Journal:  J Natl Compr Canc Netw       Date:  2009-04       Impact factor: 11.908

Review 9.  Advances in the diagnosis, evaluation and management of cholangiocarcinoma.

Authors:  Pankaj Singh; Tushar Patel
Journal:  Curr Opin Gastroenterol       Date:  2006-05       Impact factor: 3.287

10.  Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study.

Authors:  Tania M Welzel; Barry I Graubard; Hashem B El-Serag; Yasser H Shaib; Ann W Hsing; Jessica A Davila; Katherine A McGlynn
Journal:  Clin Gastroenterol Hepatol       Date:  2007-08-06       Impact factor: 11.382

View more
  11 in total

1.  Epidemiology and Risk Factors of Cholangiocarcinoma.

Authors:  Martha M Kirstein; Arndt Vogel
Journal:  Visc Med       Date:  2016-12-01

2.  Analysis of viral integration reveals new insights of oncogenic mechanism in HBV-infected intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma.

Authors:  Linghao Zhao; Yuyouye Wang; Tao Tian; Xinjie Rao; Wei Dong; Jinmin Zhang; Yuan Yang; Qifei Tao; Fang Peng; Chenhang Shen; Songbo Wang; Hui Liu; Xi Zeng; Weiping Zhou
Journal:  Hepatol Int       Date:  2022-09-20       Impact factor: 9.029

3.  Integrated computational approaches to screen gene expression data to determine key genes and therapeutic targets for type-2 diabetes mellitus.

Authors:  Fahad A Alhumaydhi
Journal:  Saudi J Biol Sci       Date:  2022-02-10       Impact factor: 4.052

4.  Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).

Authors:  Jesus M Banales; Vincenzo Cardinale; Guido Carpino; Marco Marzioni; Jesper B Andersen; Pietro Invernizzi; Guro E Lind; Trine Folseraas; Stuart J Forbes; Laura Fouassier; Andreas Geier; Diego F Calvisi; Joachim C Mertens; Michael Trauner; Antonio Benedetti; Luca Maroni; Javier Vaquero; Rocio I R Macias; Chiara Raggi; Maria J Perugorria; Eugenio Gaudio; Kirsten M Boberg; Jose J G Marin; Domenico Alvaro
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-04-20       Impact factor: 46.802

Review 5.  Multidisciplinary Care of Patients with Intrahepatic Cholangiocarcinoma: Updates in Management.

Authors:  Kelly J Lafaro; David Cosgrove; Jean-Francois H Geschwind; Ihab Kamel; Joseph M Herman; Timothy M Pawlik
Journal:  Gastroenterol Res Pract       Date:  2015-05-19       Impact factor: 2.260

6.  Prognostic impact of hepatitis B or C on intrahepatic cholangiocarcinoma.

Authors:  Jung Woong Seo; Byung Soo Kwan; Young Koog Cheon; Tae Yoon Lee; Chan Sup Shim; So Young Kwon; Won Hyeok Choe; Byung Chul Yoo; Jeong Min Yoon; Jung Hoon Lee
Journal:  Korean J Intern Med       Date:  2020-01-10       Impact factor: 2.884

Review 7.  New insights into cholangiocarcinoma: multiple stems and related cell lineages of origin.

Authors:  Maria Consiglia Bragazzi; Lorenzo Ridola; Samira Safarikia; Sabina Di Matteo; Daniele Costantini; Lorenzo Nevi; Vincenzo Cardinale
Journal:  Ann Gastroenterol       Date:  2017-11-02

Review 8.  The biology of Hepatocellular carcinoma: implications for genomic and immune therapies.

Authors:  Galina Khemlina; Sadakatsu Ikeda; Razelle Kurzrock
Journal:  Mol Cancer       Date:  2017-08-30       Impact factor: 27.401

9.  Intrahepatic cholangiocarcinoma in the setting of HBV-related cirrhosis: Differentiation with hepatocellular carcinoma by using Intravoxel incoherent motion diffusion-weighted MR imaging.

Authors:  Yi Wei; Feifei Gao; Dandan Zheng; Zixing Huang; Min Wang; Fubi Hu; Chenyang Chen; Ting Duan; Jie Chen; Likun Cao; Bin Song
Journal:  Oncotarget       Date:  2017-12-26

10.  Negative impact of hepatitis B surface seroclearance on prognosis of hepatitis B-related primary liver cancer.

Authors:  Cheng Lou; Tong Bai; Le-Wei Bi; Ying-Tang Gao; Zhi Du
Journal:  World J Clin Cases       Date:  2018-08-16       Impact factor: 1.337

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.